Literature DB >> 10893006

Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI.

H Schultz1, E Csernok, A Schuster, T S Schmitz, M Ernst, W L Gross.   

Abstract

This study was performed to examine the prevalence and clinical correlates of bactericidal/permeability-increasing protein anti-neutrophil cytoplasmic antibodies (BPI-ANCA) in pediatric cystic fibrosis (CF) patients and to elucidate their possible role in CF pulmonary pathology. Sera of 27 CF patients were tested for ANCA by indirect immunofluorescence (IFT) and by enzyme-linked immunosorbent assay (ELISA) for ANCA sub-specificities. BPI-ANCA were examined by using standard ELISA for BPI, lipopolysaccharide-binding protein (LBP), and BPI/LBP fusion proteins to epitope map the main binding sites and look for cross-reactivity with LBP. Pulmonary function and serum concentrations of total immunoglobulin G (IgG) were measured and infections were diagnosed. In addition, release of reactive oxygen species (ROS) by neutrophil granulocytes was measured after stimulation with monoclonal BPI-ANCA. Using IFT, two patients showed atypical ANCA staining, six patients exhibited perinuclear ANCA staining, and no cytoplasmic ANCA staining was detected. Of 27 patients, 13 (48%) were BPI-ANCA (IgG) positive, and three were also immunoglobulin A (IgA) BPI-ANCA positive; one patient had ANCA against lactoferrin; and no proteinase 3 ANCA was detected in any of the patients. All BPI-ANCA bound to the C-terminal region of the molecule; none bound to the N-terminus or to LBP. There was no significant correlation between clinical data and the occurrence of BPI-ANCA in this cross-sectional study. Release of ROS from granulocytes was induced by monoclonal BPI-ANCA. Activation of neutrophils and possible modulation of BPI-mediated opsonophagocytosis and disposal of Gram-negative bacteria and lipopolysaccharides by BPI-ANCA raise the possibility that they contribute to pulmonary pathology in pediatric CF patients but intervention longitudinal studies in large groups of patients are needed to establish a causative association.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893006     DOI: 10.1034/j.1399-3038.2000.00069.x

Source DB:  PubMed          Journal:  Pediatr Allergy Immunol        ISSN: 0905-6157            Impact factor:   6.377


  11 in total

Review 1.  The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.

Authors:  Hendrik Schultz; Jerrold P Weiss
Journal:  Clin Chim Acta       Date:  2007-07-13       Impact factor: 3.786

Review 2.  Autoantibodies in primary sclerosing cholangitis.

Authors:  Johannes-Roksund Hov; Kirsten-Muri Boberg; Tom-H Karlsen
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

3.  Expression and antimicrobial function of bactericidal permeability-increasing protein in cystic fibrosis patients.

Authors:  Diana Aichele; Markus Schnare; Marc Saake; Martin Röllinghoff; Andre Gessner
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

4.  Predicting bacterial infection risk in patients with ANCA-associated vasculitis in southwest China: development of a new nomogram.

Authors:  Naidan Zhang; Jiaxiang Sun; Chaixia Ji; Xiao Bao; Chenliang Yuan
Journal:  Clin Rheumatol       Date:  2022-08-02       Impact factor: 3.650

5.  BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.

Authors:  H Schultz; S Schinke; J Weiss; V Cerundolo; W L Gross; S Gadola
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

6.  Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA).

Authors:  M V Talor; J H Stone; J Stebbing; J Barin; N R Rose; C L Burek
Journal:  Clin Exp Immunol       Date:  2007-07-05       Impact factor: 4.330

Review 7.  Killing three birds with one BPI: Bactericidal, opsonic, and anti-inflammatory functions.

Authors:  Jomkuan Theprungsirikul; Sladjana Skopelja-Gardner; William F C Rigby
Journal:  J Transl Autoimmun       Date:  2021-05-28

8.  Differential Enhancement of Neutrophil Phagocytosis by Anti-Bactericidal/Permeability-Increasing Protein Antibodies.

Authors:  Jomkuan Theprungsirikul; Sladjana Skopelja-Gardner; Rachel M Wierzbicki; Katherine J Sessions; William F C Rigby
Journal:  J Immunol       Date:  2021-07-16       Impact factor: 5.426

Review 9.  Neutrophil anti-neutrophil cytoplasmic autoantibody proteins: bactericidal increasing protein, lactoferrin, cathepsin, and elastase as serological markers of inflammatory bowel and other diseases.

Authors:  Kallirroi S Kyriakidi; Vasileios E Tsianos; Evaggelos Karvounis; Dimitrios K Christodoulou; Konstantinos H Katsanos; Epameinondas V Tsianos
Journal:  Ann Gastroenterol       Date:  2016-03-24

10.  Low-Avidity Autoantibodies against Bactericidal/Permeability-Increasing Protein Occur in Gram-Negative and Gram-Positive Bacteremia.

Authors:  J Theprungsirikul; J T Thaden; R M Wierzbicki; A S Burns; S Skopelja-Gardner; V G Fowler; K L Winthrop; I W Martin; W F C Rigby
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.